Nice catch DJ and great question. Why weren’t all the

New Post Public Reply Private Reply Replies (3) Message Board
Mhill DJknows #54477
651
Nice catch DJ and great question. Why weren’t all the reports amended since they all required the same correction? Why do just the 2 then have to go back and do the others? This long, drawn out process is beginning to feel all too uneasy. Doc, can we get some answers and direction here!?
2

Univec Conglomerate Inc (UNVC) Stock Research Links

UNVC Board Company Profile Buy Rating Time & Sales News Filings Financials
$UNVC$
Scroll down for more posts ▼

Top 10 Most Recent News Articles

KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 9

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 123

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 52

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 422

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 175

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 104

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 0

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 432

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 287

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
YSTUDIO's Pens: A Nod to the Power of Writing

Updated Category News Views 557

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Continue Reading

Top 5 Most Recently Viewed Articles

Laugh Factory's Annual Free Thanksgiving Feast Returns to Hollywood

Updated Category News Views 239

Laugh Factory's Holiday Tradition: A Thanksgiving Feast The world-renowned Laugh Factory in Hollywood proudly continues its cherished tradition by hosting the 45th consecutive annual free Thanksgiving feast. This Thanksgiving, the club opens its doors for four seatings at 1 p.m., 3 p.m., 5 p.m., and 7 p.m., offering an incredible opportunity for community members to come...

Continue Reading
Recognizing Thomas Edwards Jr.: A Champion of Justice

Updated Category News Views 275

Celebrating Excellence in Legal Advocacy Attorney Thomas S. Edwards, Jr., a Senior Partner at Edwards & Ragatz, P.A., has been honored with the prestigious "Compassionate Gladiator Award" by the Florida Justice Association (FJA). This esteemed award is presented to legal professionals who exhibit exceptional dedication to their clients and the legal system, reflecting the...

Continue Reading
Growth Journey of Plant-Based Dairy: Trends and Insights

Updated Category News Views 283

Exploring the Plant-Based Dairy Products Market The plant-based dairy products market is witnessing remarkable growth, driven by evolving consumer preferences and increasing awareness regarding health benefits and sustainability practices. Initially valued at USD 20 billion, market experts project it to reach USD 34 billion by 2030, fueled by a promising CAGR of 9%...

Continue Reading
Catch the Excitement of Monster Jam at Northern Tool + Equipment

Updated Category News Views 138

Monster Jam Hits Northern Tool + Equipment in Oklahoma City Northern Tool + Equipment is thrilled to announce an upcoming event that promises to be packed with excitement and entertainment for the community. This special day will spotlight a legendary Monster Jam truck, bringing the high-octane thrill of motorsports to local fans. Exclusive Offers for Customers As part of...

Continue Reading
Analyzing NVIDIA’s Competitive Edge in Semiconductor Sector

Updated Category News Views 214

Understanding NVIDIA's Role in the Semiconductor Industry In the fast-paced world of technology, evaluation of companies within specific sectors is vital for investors and enthusiasts. This article focuses on NVIDIA (NASDAQ: NVDA), a leader in the Semiconductors & Semiconductor Equipment industry, and compares its performance with key competitors. By analyzing crucial...

Continue Reading